Literature DB >> 10815925

Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.

M Oelke1, U Moehrle, J L Chen, D Behringer, V Cerundolo, A Lindemann, A Mackensen.   

Abstract

Tumor antigens that might serve as potential targets for adoptive T-cell therapy have been defined in different tumor entities, especially in malignant melanoma. To generate conditions to induce primary T-cell responses against different HLA-A*0201-restricted melanoma peptides and to allow further expansion of peptide-specific T cells for adoptive transfer, CD8+-purified T cells from healthy donors were stimulated with Melan-A-pulsed autologous dendritic cells. Dendritic cells were generated in vitro from monocytes with granulocyte macrophage colony-stimulating factor, interleukin-4, and transforming growth factor-beta1. After 3-4 weekly stimulation cycles with Melan-A-pulsed DCs, we were able to induce a strong peptide-specific CTL response in vitro. MHC-peptide tetramer staining revealed a frequency of up to 3.5% CD8+/Melan-A+ T cells. Additional antigen-independent expansion with anti-CD3/anti-CD28 monoclonal antibodies together with interleukin-2 gave rise to 600-fold expansion of CD8+ CTLs that maintained Melan-A specificity and were able to efficiently lyse Melan-A-expressing melanoma cells. To enrich antigen-specific T cells in vitro, we used a recently established technology for analysis and sorting of live cells according to secreted cytokines. In the present study, we demonstrated that Melan-A-specific T cells can be purified by magnetic separation according to secreted IFN-gamma. These cells revealed a very potent monospecific CTL response, even at low E:T ratios, against Melan-A-pulsed and Melan-A-expressing target cells. Altogether, our study demonstrated that we have developed an efficient method for generating large numbers of peptide-specific T cells in vitro that may be used for adoptive T-cell transfer in tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815925

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Authors:  John W Hickey; Jonathan P Schneck
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

2.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

3.  Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Authors:  A Escobar; M López; A Serrano; M Ramirez; C Pérez; A Aguirre; R González; J Alfaro; M Larrondo; M Fodor; C Ferrada; F Salazar-Onfray
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

4.  Dynamic regulation of functionally distinct virus-specific T cells.

Authors:  Zaza M Ndhlovu; Mathias Oelke; Jonathan P Schneck; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

5.  Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells.

Authors:  Matthias Wölfl; Philip D Greenberg
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

6.  Effect of neutrophil apoptosis on monocytic cytokine response to Porphyromonas gingivalis lipopolysaccharide.

Authors:  Ezel Berker; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2005-06       Impact factor: 6.993

7.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

8.  Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

Authors:  Eduardo Huarte; Jan Fisher; Mary Jo Turk; Diane Mellinger; Cathy Foster; Benita Wolf; Kenneth R Meehan; Camilo E Fadul; Marc S Ernstoff
Journal:  Cancer Lett       Date:  2009-06-06       Impact factor: 8.679

9.  Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes.

Authors:  Hawley C Pruitt; Daniel Lewis; Mark Ciccaglione; Sydney Connor; Quinton Smith; John W Hickey; Jonathan P Schneck; Sharon Gerecht
Journal:  Matrix Biol       Date:  2019-02-16       Impact factor: 11.583

10.  Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy.

Authors:  John W Hickey; Yi Dong; Jae Wook Chung; Sebastian F Salathe; Hawley C Pruitt; Xiaowei Li; Calvin Chang; Andrew K Fraser; Catherine A Bessell; Andrew J Ewald; Sharon Gerecht; Hai-Quan Mao; Jonathan P Schneck
Journal:  Adv Mater       Date:  2019-04-10       Impact factor: 30.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.